As previously communicated, the data were generated through treatment outcomes in real world settings from centers in Valencia, Spain and Bologna, Italy and underscore the growing interest in real-world clinical use of Pepaxti.

The Italian study reports an overall response rate (ORR) of 47 percent in a heavily pretreated patient population with relapsed or refractory multiple myeloma, confirming the efficacy previously demonstrated in the HORIZON trial with a similar safety profile. Importantly, the study demonstrated efficacy in patients treated with novel immunotherapies, underscoring the robust effectiveness of Pepaxti in daily clinical practice.

The Spanish study confirms the efficacy of Pepaxti in an even more heavily pretreated patient population where the majority of patients had been exposed to either anti-BCMA or anti-GPRC5D immunotherapy, generating data highly relevant to clinicians seeking guidance for treatment decisions.

Both studies confirm Pepaxti’s favorable tolerability profile in real-world settings – a key consideration in multiple myeloma where safety challenges are common.

"These real-world data show that Pepaxti delivers compelling and meaningful outcomes for patients outside the controlled environment of clinical trials," says Stefan Norin, Chief Medical Officer at Oncopeptides. "The results confirm a positive clinical experience with Pepaxti, highlight its tolerability with manageable side effects, and provide highly relevant insights for physicians and payers in markets where treatment decisions increasingly rely on real-world evidence."

The abstracts are available here. For further information, please visit www.oncopeptides.com.